MAT-HEM-00745 Quality Intervention for MF Video

Hello, I’m Julianne Orr, and I’m happy to be partnering with Incyte to show you how you can implement a quality initiative for patients with myelofibrosis, or MF.

An important component of managing patients with MF is risk stratification. Risk stratification is recommended for all patients with MF by the NCCN Guidelines®.

However, the following data, from an Incytesponsored, retrospective chart review of 338 patients with MF, indicated that 64% of patients were either inaccurately risk stratified or not risk stratified at diagnosis.

After applying risk stratification criteria, the investigators found that approximately 95% of patients in this study had intermediate- or high-risk MF at diagnosis.

So, how do we take a proactive approach to monitoring and assessing risk factors in patients with myelofibrosis ?

The prognostic risk factors listed here have been identified as independent predictors of shortened survival. The presence of just one of these risk factors, such as an age greater than 65 years, indicates that the patient has intermediate-risk myelofibrosis.

Unfortunately, median life expectancy decreases as the number of risk factors increase. The findings shown here are from a retrospective assessment of 1054 patients with primary MF. So how do we as pharmacists help ensure our patients are being correctly risk stratified?

We can take an active role in identifying risk by evaluating electronic health records.

Here are steps you can follow to create a list of patients for a potential quality intervention. Step 1: Select the query, report, or list tab within your system. Step 2: Enter ICD-10 Code D75.81 for MF. Step 3: Evaluate for the presence of any risk factors monthly. Step 4: Document the updated risk category within your system for provider consideration.

When you identify patients with new risk profiles, share your findings with their clinicians. This is crucial, as your clinicians can use this information in assessing their patients.

And remember, just one risk factor indicates the patient has intermediaterisk myelofibrosis.